Mouse Anti-CDK13 Recombinant Antibody (1B3-1B11) (CBMAB-C3643-LY)

Name: Mouse Anti-CDK13 Recombinant Antibody (1B3-1B11)
SKU: CBMAB-C3643-LY
Rating: 5 (1 reviews)

See all CDK13 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

1B3-1B11

Application

WB, ELISA, IF

Immunogen

CDC2L5 (1 a.a. ~ 325 a.a) full length recombinant protein.

Host Species

Mouse

Specificity

Human, Mouse, Rat

Antibody Isotype

IgG1, κ

Clonality

Monoclonal Antibody

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Application	Note
IF(ICC)	10 μg/ml

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS

Preservative

None

Concentration

Batch dependent

Purity

> 95% Purity determined by SDS-PAGE.

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

More Infomation

Target

Full Name

Cyclin Dependent Kinase 13

Introduction

CDK13 (Cyclin Dependent Kinase 13) is a Protein Coding gene.
Diseases associated with CDK13 include Congenital Heart Defects, Dysmorphic Facial Features, And Intellectual Developmental Disorder and Corneal Endothelial Dystrophy.
Among its related pathways are Innate Immune System and Gene Expression.
Gene Ontology (GO) annotations related to this gene include protein kinase activity.
An important paralog of this gene is CDK12.

Entrez Gene ID

8621

UniProt ID

Q14004

Alternative Names

Cyclin Dependent Kinase 13; Cholinesterase-Related Cell Division Controller; Cell Division Cycle 2-Like Protein Kinase 5; Cell Division Protein Kinase 13; CDC2-Related Protein Kinase 5; EC 2.7.11.22; CDC2L5; HCDK13; CDC2L;

Function

Cyclin-dependent kinase which displays CTD kinase activity and is required for RNA splicing. Has CTD kinase activity by hyperphosphorylating the C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit RPB1, thereby acting as a key regulator of transcription elongation. Required for RNA splicing, probably by phosphorylating SRSF1/SF2. Required during hematopoiesis. In case of infection by HIV-1 virus, interacts with HIV-1 Tat protein acetylated at 'Lys-50' and 'Lys-51', thereby increasing HIV-1 mRNA splicing and promoting the production of the doubly spliced HIV-1 protein Nef.

Biological Process

Alternative mRNA splicing, via spliceosome Source: UniProtKB
Hemopoiesis Source: UniProtKB
Multicellular organism development Source: ProtInc
Negative regulation of stem cell differentiation Source: Ensembl
Neutrophil degranulation Source: Reactome
Phosphorylation of RNA polymerase II C-terminal domain Source: UniProtKB
Positive regulation of cell population proliferation Source: ProtInc
Positive regulation of transcription elongation from RNA polymerase II promoter Source: GO_Central
Protein phosphorylation Source: GO_Central
Regulation of mitotic nuclear division Source: ProtInc
Transcription elongation from RNA polymerase II promoter Source: GO_Central
Viral process Source: UniProtKB-KW

Cellular Location

Nucleus speckle

Involvement in disease

Congenital heart defects, dysmorphic facial features, and intellectual developmental disorder (CHDFIDD): An autosomal dominant syndrome characterized by atrial and/or ventricular septal congenital heart defects, facial dysmorphism with hypertelorism, upslanted palpebral fissures, epicanthal folds, ptosis, strabismus, posteriorly rotated ears, thin upper lip, and small mouth. Patients manifest global developmental delay, delayed walking and speech acquisition, and intellectual disability. Some patients have mild microcephaly, a small cerebral cortex, and agenesis of corpus callosum. More variable features include clinodactyly and/or camptodactyly of the fingers, hypotonia, and joint hypermobility.

Ramírez-Moya, J., Miliotis, C., Baker, A. R., Gregory, R. I., Slack, F. J., & Santisteban, P. (2021). An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks. Molecular cancer, 20(1), 1-20.

Wang, J., Zhang, Y., Lu, L., Lu, Y., Tang, Q., & Pu, J. (2019). Insight into the molecular mechanism of LINC00152/miR‐215/CDK13 axis in hepatocellular carcinoma progression. Journal of cellular biochemistry, 120(11), 18816-18825.

Baniya, S. (2019). Validating CDK13 as a Novel Dependency in Acute Myeloid Leukemia (Doctoral dissertation, Wellesley College).

Hamilton, M. J., & Suri, M. (2019). CDK13-related disorder. Advances in genetics, 103, 163-182.

Hampl, M., Novakova, M., Kavkova, M., Zikmund, T., Kohoutek, J., Kaiser, J., & Buchtová, M. (2019). Cdk13-/-Mice Exhibit Developmental Delay and Craniofacial Malformations during Embryonic Development.

Quereda, V., Bayle, S., Vena, F., Frydman, S. M., Monastyrskyi, A., Roush, W. R., & Duckett, D. R. (2019). Therapeutic targeting of CDK12/CDK13 in triple-negative breast cancer. Cancer Cell, 36(5), 545-558.

van den Akker, W. M. R., Brummelman, I., Martis, L. M., Timmermans, R. N., Pfundt, R., Kleefstra, T., ... & Schuurs‐Hoeijmakers, J. H. M. (2018). De novo variants in CDK13 associated with syndromic ID/DD: molecular and clinical delineation of 15 individuals and a further review. Clinical genetics, 93(5), 1000-1007.

Uehara, T., Takenouchi, T., Kosaki, R., Kurosawa, K., Mizuno, S., & Kosaki, K. (2018). Redefining the phenotypic spectrum of de novo heterozygous CDK13 variants: Three patients without cardiac defects. European journal of medical genetics, 61(5), 243-247.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-CDK13 Recombinant Antibody (1B3-1B11)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Mouse Anti-CDK13 Recombinant Antibody (3G1) (CAT#: CBMAB-A1393-LY)

Mouse Anti-CDK13 Recombinant Antibody (CBFYC-1592) (CAT#: CBMAB-C1651-FY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry